Towards Healthcare
Lipid Nanoparticle Raw Materials Market Size | 5.67% - CAGR by 2033

Lipid Nanoparticle Raw Materials Market Size (USD 467.49 Mn) by 2033

The report covers Lipid Nanoparticle Raw Materials Market Trends and Segments by product, disease indication, application and region. Products include ionizable lipids, PEGylated lipids, sterol lipids, neutral phospholipids, kits, reagents and other raw materials. Disease indications cover cancer, infectious diseases, blood diseases and others. Applications are divided into therapeutics and research. The report offers the value (in USD Million) for the above segments.

Lipid Nanoparticle Raw Materials Market Size and Future Growth Analysis

The global lipid nanoparticle raw materials market size was estimated at US$ 269.31 million in 2023 is to reach around US$ 467.49 million by 2033. Projected to grow at a compounded annual growth rate (CAGR) of 5.67% from 2024 to 2033. The need for better drug delivery systems for enhanced performance drives the market’s growth.

Lipid Nanoparticle Raw Materials Market Revenue 2023 - 2033

Unlock Infinite Advantages: Subscribe to Annual Membership

Key Takeaways

  • North America dominated the market with the largest revenue share of 41% in 2023.
  • By product, the kits segment has held a major revenue share of 55% in 2023.
  • By disease indication, the infectious diseases segment has contributed more than 47% of revenue share in 2023.
  • By disease indication, the cancer segment is expected to expand at a solid CAGR during the forecast period.
  • By application, the therapeutics segment has generated more than 63% of revenue in 2023.
  • By application, the research segment is estimated to grow at the fastest CAGR during the forecast period.

Industry at a Glance

The lipid nanoparticle raw materials market deals with the production and distribution of raw materials used in the development of lipid nanoparticles. The four main components of lipophilic nanoparticles (LNPs) are cationic or ionizable lipids, which bind to negatively charged biological material and facilitate endosomal escape; phospholipids, which give the particle structure; cholesterol, which facilitates membrane fusion and adds stability to the nanoparticles; and pegylated lipids, which enhance the stability and circulation of the nanoparticles. Lipid-based nanoparticles are known as LNPs. A unique pharmaceutical formulation and a novel pharmaceutical drug delivery system are what they are. The discovery of Doxil®, the first small-molecule liposomal preparation to get FDA approval in 1995, marked a turning point in the study of lipid-based nanocarriers, which is now progressing quickly in the fields of biologics delivery and cancer treatment. The pharmaceutical industry has seen a rise in the use of LNPs as potential delivery systems for a range of medicines.

Top Companies in the Lipid Nanoparticle Raw Materials Market

  • Polysciences, Inc.
  • NOF AMERICA CORPORATION
  • Biopharma PEG Scientific Inc.
  • Creative Biolabs
  • CordenPharma International
  • Tebubio
  • Avanti Polar Lipids
  • Hopewell Therapeutics
  • Echelon Biosciences
  • Merck KGaA
  • BroadPharm
  • Cytiva

Recent Development by Hopewell Therapeutics in the Lipid Nanoparticle Raw Materials Market

Company Name Hopewell Therapeutics
Headquarters Massachusetts
Recent Development In May 2024, a biotechnology company, Hopewell Therapeutics, is dedicated to the discovery, synthesis, and development of the next generation of tissue-targeted lipid nanoparticles (ttLNPs) for the delivery of genomic medicines to patients. Today, the company announced that it will virtually attend the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting this week in Baltimore, MD, to present preclinical data showing the progression of its vaccine, oncology, and pulmonary programs.

Recent Development by Cytiva in the Lipid Nanoparticle Raw Materials Market

Company Name Cytiva
Headquarters U.S.
Recent Development In July 2023, the commercial formulation method NanoAssemblr was introduced by Cytiva, a leading company in the life sciences industry, with the aim of producing lipid nanoparticle therapeutics for both clinical and commercial use. Companies can use the fully compliant and automated instrumentation of the NanoAssemblr commercial formulation system to bring these medications to market by utilizing a single, scalable mixing technology for all phases of development, from large-scale manufacturing to product development and research.

Sophisticated Drug Delivery Systems Drives the Market’s Growth

Lipid nanoparticles have several advantages over many delivery systems used in therapeutics, which increases the usage of LNPs and, hence, the growth of the lipid nanoparticle raw materials market. One of the best methods for efficiently delivering antibiotics, nucleic acid therapies, and cytotoxic chemotherapeutic drugs is the use of liposome nanoparticles or LNPs. The main reason for their success is their intriguing physicochemical behaviors, which include high bioavailability, multiple routes of administration, large-scale production, intrinsic blood-brain barrier crossing ability, and the capacity to deliver macromolecules like DNA, oligonucleotides, and proteins. Oral and parenteral medication delivery methods can be based on solid lipid nanoparticles. The advantages of polymeric nanoparticle and lipid emulsion systems combined in SLNs also solve the problems with in vivo stability and timing that plague both polymeric nanoparticles and traditional drug delivery methods.

Burst Release System Restraints the Market Growth

The growth of the lipid nanoparticle raw materials market is restricted due to the burst release system. The possibility of systemic burst release is a significant hurdle in LNPs research. Changes in the lipid matrix, surfactant content, and production-related factors (such as temperature) can all have a substantial impact on the drug-release profile of LNPs. Furthermore, critical elements of the manufacturing process, such as temperature, surfactant content, and intrinsic properties of the lipid matrix, influence the release of the medication from lipid nanoparticles.

Gene Therapy Creates Opportunity for the Lipid Nanoparticle Raw Materials Market

The therapeutic potential of genetic therapeutics based on RNA or DNA is extraordinary since almost every illness may be addressed by editing faulty genes, producing a helpful protein, or suppressing a dangerous gene. To bring these macromolecules into the inside of target cells, nucleic acid polymer-based medicines need advanced delivery mechanisms. The ability of LNPs to prevent encapsulated nucleic acids from degrading is one of its main benefits. Around the genetic material, the cationic lipids form a barrier that prevents them from being broken down by nucleases or exposed to extreme weather. As said, the technology for small molecule medicinal compositions using LNPs is very advanced. Proteins and nucleic acids are examples of biological components that are encapsulated in LNP, a recently developed kind of medicinal formulation.

Report Highlights

Product Insights

By product, the kits segment led the lipid nanoparticle raw materials market with the largest share in 2023. Different formulations of lipid nanoparticles (LNPs) may be needed for different therapeutic uses. With the use of kits, LNPs may be created with specific target cells, tissues, and therapeutic goals in mind. Kits make it easier to optimize iteratively, so you may gradually increase the stability, safety, and efficiency of LNP formulations.

For instance,

  • In February 2024, the development of messenger RNA (mRNA)-based medicines, such as gene therapies or mRNA vaccines, became possible through the introduction of CordenPharma International's innovative Lipid NanoParticle (LNP) Starter Kits. In order to enable researchers and developers to construct and optimize their own LNPs for mRNA delivery, starting kits are intended to contain all the necessary components. Sterols, helper lipids, ionizable lipids, and PEGylated lipids are the four essential lipids included in the new LNP kits.

Disease Indication Insights

By disease indication, the infectious diseases segment dominated the lipid nanoparticle raw materials market in 2023. The development of novel and current medications in nano-sized carriers holds the potential to address a number of issues related to the management of these illnesses, such as low on-target bioavailability, drug accumulation that is subtherapeutic in microbial havens and reservoirs, and low patient adherence brought on by toxicities connected to the medications and lengthy treatment regimens. Nanocarriers may also be utilized to create vaccinations, which are a powerful tool in the battle against infectious illnesses.

As of 2023, infectious illnesses continue to be one of the major global causes of morbidity and mortality, accounting for almost 52 million (33%) of all deaths globally. There is still a 50% chance that infectious illnesses may resurface and spread among the world's population. According to current data, there are an estimated 14 million pediatric fatalities worldwide each year, with vaccine-preventable illnesses accounting for 70% of these deaths and poor nations accounting for 99% of all pediatric deaths.

By disease indication, the cancer segment is expected to grow at the fastest rate during the forecast period. The most cutting-edge and extensively used delivery methods for nucleic acids and small compounds are lipid-based NPs. In the context of cancer immunotherapy, lipid-based NPs have the ability to ex-vivo construct cancer cell treatments with a comparable level of effectiveness to that of other non-viral or viral vectors, in addition to delivering small compounds and mRNA therapies in vivo to reach tremendous antitumor efficacy.

The rising worldwide cancer incidence, its uneven effect on vulnerable populations, and the urgent necessity of tackling cancer inequalities are highlighted by the IARC estimates. The greatest data sources that countries will have in 2022 will serve as their foundation. For 2022, it was projected that there would be 20 million new cases of cancer and 9.7 million deaths from the disease. Five years after receiving a cancer diagnosis, an estimated 53.5 million individuals were still living. Five percent of people will have cancer in their lives; nine percent of men and twelve percent of women will die from the disease.

Global New Cancer Cases in 2024 - 2045

Application Insights

By application, the therapeutics segment led the lipid nanoparticle raw materials market with the largest share in 2023. Because of their chemical and physical instability, therapeutic proteins are extremely delicate molecules. In addition to keeping the therapeutic protein structure safe from degradation, the lipid nanoparticle shape makes the protein more bioavailable and capable of passing across membranes. Lipid nanoparticles meet all the necessary conditions to be utilized as an ideal drug delivery mechanism, including the ability to entrap proteins and other hydrophilic and lipophilic substances. Therapeutic proteins have significant limitations that can be addressed, and entirely new prospects can be opened by encasing the therapeutic proteins in lipid nanoparticles.

By application, the research segment is estimated to grow at the fastest CAGR during the forecast period. At the vanguard of the quickly evolving subject of nanotechnology are solid lipid nanoparticles, which have a variety of potential uses in clinical treatment, research, medication delivery, and other diverse disciplines. Lipid nanoparticles provide a promising avenue for the development of novel therapies because of their distinct size-dependent characteristics. The capacity to encapsulate medications into nanocarriers presents a novel drug delivery model that may be applied to secondary and tertiary drug targeting. Therefore, researchers have focused a lot of attention on solid lipid nanoparticles because they show tremendous potential for achieving the objective of regulated and site-specific drug delivery.

Regional Insights

By region, North America dominated the lipid nanoparticle raw materials market in 2023. North America is known for its advancements in technology and healthcare. A huge amount of investment is made to conduct proper research and development in order to fulfill the healthcare demand in different categories. The U.S. is among the dominant countries that promote the growth of the lipid nanoparticle raw materials market globally and in the North American region. Several factors contribute to that dominance, among which one is research and development in the healthcare sector.

For instance,

  • In 2023, the Global Health Research and Development Strategy 2023–2028 was unveiled by the U.S. Agency for International Development (USAID). In order to improve health outcomes worldwide, USAID has redoubled its commitment to research and development (R&D) and the application of cutting-edge health products and technologies. It has also increased the implementation and scale-up of real-world, evidence-based research and learning, and it has strengthened local and international partnerships for R&D in the field of health.

The growing prevalence of infectious diseases brought on by the application of lipid nanoparticles in infection therapy is another factor propelling the growth of the lipid nanoparticle raw materials market in the U.S.. Every year in the US, there are more than 48 million instances of diarrhea, which leads to 128,000 hospital admissions and 3,000 deaths from diarrheal illnesses. Lipid nanoparticle research is becoming increasingly significant due to the rising number of cancer patients in the United States. Based on U.S. demographic data, ten million cancer-related deaths and twenty million new instances of the illness are anticipated each year.

Cancer Cases in the U.S. in 2023 - 2040

Canada is the second-largest contributor to the expansion of the lipid nanoparticle raw materials market, behind the U.S.. !9 million dollars in funding will be used by 2024 to integrate researchers into health system organizations nationwide. In order to meaningfully contribute to strengthening Canada's healthcare system and guarantee that Canadians receive high-quality medical care, the government of Canada is funding researchers across the nation who are working with health system organizations. Researchers may assist in identifying and implementing answers to the problems that this nation's health systems are confronting by becoming embedded in organizations that support the health system.

For instance,

  • In April 2024, the Canadian government revealed intentions to significantly increase funding for both education and research, including additional expenditures for student grants, research infrastructure, and artificial intelligence. Through Canada's regional development agencies, C$200 million is set aside for AI research and development with the goal of integrating AI into industry, clean tech, agriculture, and health care.

Recent Developments

  • In January 2024, in order to produce an in vivo gene editing solution for a rare liver condition, Tome Biosciences' programmable genomic integration (PGI) expertise and Genevant Sciences' lipid nanoparticle technology might get Genevant Sciences approximately $114 million in compensation. Only that the overall value of the arrangement may exceed $114.3 million, along with tiered royalties on sales of any ensuing medicine, were disclosed by Genevant, leaving the specifics of the contract unclear.
  • In October 2023, the LNP delivery platform powered by artificial intelligence (AI) was revealed by Mana.bio. Mana.bio is supported by an oversubscribed $19.5 million seed financing round. Its AI-native methodology for developing innovative lipid chemistry and LNP formulation design sets it apart from the competition. The funding opens the door to new therapeutic possibilities for a variety of unmet needs by allowing Mana.bio to continue developing its unique, specially designed AI LNP platform, which will enable it to more safely and efficiently deliver RNA and gene treatments to particular extrahepatic areas in the body.
  • In September 2023, GenScript Biotech Corporation, the world's foremost provider of instruments and services for life-science research, added specialized lipid nanoparticle (LNP) and circular RNA (circRNA) formation capabilities to its IVT mRNA synthesis offering. As part of its dedication to providing cutting-edge reagents that enable research in gene and cell therapy, vaccine development, and protein replacement treatments, GenScript is now offering these additional contract-manufactured reagent services.
  • In July 2023, in its pharmaceutical production facility located in Wuxi City, China, WuXi STA introduced a fully automated, high-potency sterile injectable line. The new line can produce 12 million units a year. Furthermore, the Wuxi City location now houses the company's sterile lipid nanoparticle platform, which can produce batches of up to 50 liters. This platform is designed to enable the formulation and development of complicated novel modalities, particularly those involving oligonucleotide-based therapeutic candidates. WuXi STA intends to expand its injectable manufacturing operations by adding two more lines at the current location by 2024. Additionally, new lines will be installed in Couvet, Switzerland, and at the future Middletown facility in Delaware.

Segments Covered in Lipid Nanoparticle Raw Materials Market Report

By Product

  • Ionizable Lipids
  • PEGylated Lipids
  • Sterol Lipids
  • Neutral Phospholipids
  • Kits
  • Reagents
  • Other Raw Materials

By Disease Indication

  • Cancer
  • Infectious Diseases
  • Blood Diseases
  • Others

By Application

  • Therapeutics
  • Research

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.

FAQ's

The lipid nanoparticles range from 1=50 to 1000 nm.

LNPs are used for encapsulating materials, which, after encapsulation, are released into specific locations for therapeutic purposes.

WHO, National Library of Medicine, USAID, American Cancer Society, Canada.ca.